{"analyses":[{"ciLowerLimit":"0.62","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"0.92","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.0055","paramType":"Cox Proportional Hazard","paramValue":"0.75","statisticalComment":"Log-rank test stratified by LAG-3 (≥ 1% vs \\< 1%), BRAF (mutation positive vs mutation wild-type), AJCC M-stage (M0/M1any\\[0\\] vs M1any\\[1\\])","statisticalMethod":"Log Rank"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"6.37","upperLimit":"15.74","value":"10.12"},{"groupId":"OG001","lowerLimit":"3.38","upperLimit":"5.62","value":"4.63"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"355"},{"groupId":"OG001","value":"359"}],"units":"Participants"}],"description":"Progression Free Survival (PFS) is defined as the time between the date of randomization and the date of first documented tumor progression, assessed by a blinded independent central review (BICR) (per RECIST v1.1 criteria), or death due to any cause, whichever occurs first. Subjects who die without a reported progression will be considered to have progressed on the date of their death.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants receive BMS-986213 (IV fixed-dose combination relatlimab/nivolumab at a 1:3 ratio) every 4 weeks (Q4W).\n\nFor adults, dosing is relatlimab 160 mg/nivolumab 480 mg. Adolescents ≥ 40 kg will receive adult dosing; for adolescents \\< 40 kg, dosing is relatlimab 2 mg/kg/nivolumab 6 mg/kg.","id":"OG000","title":"Arm A: Relatlimab + Nivolumab"},{"description":"Participants receive Nivolumab IV monotherapy every 4 weeks (Q4W).\n\nDosing for adults is 480 mg. Adolescents ≥ 40 kg will receive adult dosing; for adolescents \\< 40 kg, dosing is 6 mg/kg.","id":"OG001","title":"Arm B: Nivolumab"}],"paramType":"MEDIAN","populationDescription":"All randomized participants","reportingStatus":"POSTED","timeFrame":"From randomization to date of first documented tumor progression or death (up to approximately 33 months)","title":"Progression Free Survival (PFS)","type":"PRIMARY","unitOfMeasure":"Months"}